T1	intervention 85 120	preoperative antibiotic prophylaxis
T2	condition 215 244	surgical site infection (SSI)
T3	eligibility 405 443	Women undergoing MRM for breast cancer
T4	intervention 826 847	intravenous cefazolin
T5	control 855 862	placebo
T7	total-participants 1061 1064	254
T9	outcome 1199 1223	overall incidence of SSI
T10	outcome 1281 1295	infection rate
T12	cv-bin-percent 1372 1376	15 %
T13	iv-bin-percent 1380 1386	13.4 %
T8	outcome 1581 1584	SSI
T14	outcome 1586 1607	incidence of hematoma
T15	outcome 1611 1617	seroma
